Literature DB >> 1560266

Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure.

A M Spence1, M S Berger, R B Livingston, F Ali-Osman, B Griffin.   

Abstract

Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1560266     DOI： 10.1007/bf00172671

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  15 in total

Review 1.  Modalities of cisplatin administration to brain tumors.

Authors:  J Shani; W Wolf
Journal:  Cancer Invest       Date:  1989       Impact factor: 2.176

2.  Intracarotid cisplatin chemotherapy for recurrent gliomas.

Authors:  M S Mahaley; S W Hipp; E J Dropcho; L Bertsch; S Cush; T Tirey; G Y Gillespie
Journal:  J Neurosurg       Date:  1989-03       Impact factor: 5.115

3.  Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.

Authors:  C L Solero; S Monfardini; C Brambilla; A Vaghi; P Valagussa; G Morello; G Bonadonna
Journal:  Cancer Clin Trials       Date:  1979

4.  Intra-arterial cisplatin for the treatment of malignant gliomas.

Authors:  H B Newton; M A Page; L Junck; H S Greenberg
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

5.  Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study.

Authors:  D J Stewart; R M O'Bryan; M Al-Sarraf; J J Costanzi; N Oishi
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

6.  Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme.

Authors:  P C Burger; P J Dubois; S C Schold; K R Smith; G L Odom; D C Crafts; F Giangaspero
Journal:  J Neurosurg       Date:  1983-02       Impact factor: 5.115

7.  Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors.

Authors:  L G Feun; S Wallace; D J Stewart; V P Chuang; W K Yung; M E Leavens; M A Burgess; N Savaraj; R S Benjamin; S E Young
Journal:  Cancer       Date:  1984-09-01       Impact factor: 6.860

8.  Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.

Authors: 
Journal:  J Neurosurg       Date:  1981-07       Impact factor: 5.115

9.  Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors.

Authors:  L G Feun; Y Y Lee; W K Yung; C Charnsangavej; N Savaraj; R A Tang; S Wallace
Journal:  Cancer Drug Deliv       Date:  1986

10.  A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.

Authors:  D F Nelson; D Schoenfeld; A S Weinstein; J S Nelson; T Wasserman; R L Goodman; S Carabell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-08       Impact factor: 7.038
View more
  9 in total

1.  Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma.

Authors:  M J van den Bent; L Pronk; P A Sillevis Smitt; C J Vecht; F A Eskens; J Verweij
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

Review 2.  Practical guidelines for the treatment of malignant gliomas.

Authors:  M C Chamberlain; P A Kormanik
Journal:  West J Med       Date:  1998-02

3.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

Review 4.  High dose chemotherapy for the treatment of malignant brain tumors.

Authors:  S H Petersdorf; R B Livingston
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 5.  New agents in the treatment of primary brain tumors.

Authors:  S A Taylor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.

Authors:  P Lunardi; J Osman Farah; L Mastronardi; F Puzzilli; F M Lo Bianco
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

7.  Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.

Authors:  Antonio Silvani; Marica Eoli; Andrea Salmaggi; Elena Lamperti; Elio Maccagnano; Giovanni Broggi; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

8.  A phase II study of intravenous carboplatin for the treatment of recurrent gliomas.

Authors:  R E Warnick; M D Prados; E E Mack; K L Chandler; F Doz; J E Rabbitt; M K Malec
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 9.  Chemotherapy for high-grade gliomas.

Authors:  E Galanis; J Buckner
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.